XLO
Xilio Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.00
−0.22%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.82
- Revenue estimate
- $4.8M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.33
- EPS estimate
- -$0.59
- Revenue actual
- $18.7M
- Revenue estimate
- $12.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +26.4%
- Revenue beats (12Q)
- 4
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026